Last reviewed · How we verify
BuproprionSR
Bupropion SR is a norepinephrine-dopamine reuptake inhibitor that increases levels of norepinephrine and dopamine in the brain by blocking their reuptake at the presynaptic neuron.
Bupropion SR is a norepinephrine-dopamine reuptake inhibitor that increases levels of norepinephrine and dopamine in the brain by blocking their reuptake at the presynaptic neuron. Used for Major depressive disorder, Seasonal affective disorder, Smoking cessation (as Zyban/Wellbutrin).
At a glance
| Generic name | BuproprionSR |
|---|---|
| Sponsor | National Institute of Mental Health (NIMH) |
| Drug class | Norepinephrine-dopamine reuptake inhibitor (NDRI) |
| Target | Norepinephrine transporter (NET) and dopamine transporter (DAT) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Mental Health |
| Phase | FDA-approved |
Mechanism of action
By inhibiting the reuptake of norepinephrine and dopamine, bupropion SR prolongs the presence of these neurotransmitters in the synaptic cleft, enhancing their signaling. This mechanism differs from selective serotonin reuptake inhibitors (SSRIs) and makes it particularly useful for depression with anhedonia or fatigue. The SR (sustained-release) formulation provides extended drug delivery over 12 hours.
Approved indications
- Major depressive disorder
- Seasonal affective disorder
- Smoking cessation (as Zyban/Wellbutrin)
Common side effects
- Insomnia
- Dry mouth
- Headache
- Nausea
- Agitation
- Seizures
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BuproprionSR CI brief — competitive landscape report
- BuproprionSR updates RSS · CI watch RSS
- National Institute of Mental Health (NIMH) portfolio CI